Healthcare Industry News: Baxter International
News Release - March 29, 2006
Baxter Names Cheryl White Corporate V.P. QualityDEERFIELD, Ill., March 29 (HSMN NewsFeed) -- Baxter International Inc. (NYSE: BAX ) announced today the promotion of Cheryl L. White to the position of corporate vice president, Quality, effective immediately. White, who had been serving in an interim capacity in the role since November of last year, will report to Baxter Chairman and CEO Robert L. Parkinson, Jr.
"We are fortunate to have an executive of Cheryl's caliber within Baxter to promote to this important position for the company," said Parkinson. "Cheryl's clear vision, strong leadership skills and significant experience in the quality environment will accelerate the progress we've made in reinvigorating innovation, quality, and reliability across Baxter's global enterprise."
White has been with Baxter for eight years, most recently as vice president, BioScience Quality Management in Westlake, Calif. She has held senior positions within the BioScience business with direct supervision over global manufacturing facilities and product development for biopharmaceutical products, biosurgery and vaccines. She played a vital leadership position in the successful validation, staffing and licensure of the ADVATE manufacturing facility in Neuchatel, Switzerland.
Prior to joining the company, she managed quality control and quality assurance activities for Hybritech, at the time a division of Eli Lilly and Beckman Instruments. In addition, she spent nine years in academic research in the University of California system.
White earned her MBA from the University of California, Irvine, and her BA in Biology from the University of California, San Diego.
Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease, and trauma. The company applies its expertise in medical devices, pharmaceuticals, and biotechnology to make a meaningful difference in patients' lives.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.